98081-50-6

Basic information

• Product Name: Acetamide, N-[4-methoxy-2-nitro-5-[3-(trifluoromethyl)phenoxy]phenyl]-
• CAS NO: 98081-50-6
• Molecular Formula: C16H13F3N2O5
• Molecular Weight: 370.285
• Mol File: 98081-50-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Acetamide, N-[4-methoxy-2-nitro-5-[3-(trifluoromethyl)phenoxy]phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-[4-methoxy-2-nitro-5-[3-(trifluoromethyl)phenoxy]phenyl]-(98081-50-6)
• EPA Substance Registry System: Acetamide, N-[4-methoxy-2-nitro-5-[3-(trifluoromethyl)phenoxy]phenyl]-(98081-50-6)

Safety Data

• Hazardous Substances Data: 98081-50-6(Hazardous Substances Data)

Upstream product

• 51-66-1 4-methoxyacetanilide 
• 6943-73-3 N-(3-bromo-4-methoxyphenyl)acetamide 
• 98-17-9 3-Trifluoromethylphenol 
• 160088-53-9 N-(5-chloro-4-methoxy-2-nitrophenyl)-acetamide 
• 7357-66-6 N-(5-bromo-4-methoxy-2-nitrophenyl)acetamide 
• 56705-78-3 potassium m-(trifluoromethyl)phenoxide 

Downstream Products

• 955995-49-0 4-{N-[4-methoxy-2-nitro-5-(trifluoromethylphenyloxy)]phenylamino}-2-butanone 
• 82333-46-8 6-methoxy-4-methyl-8-<(4-phthalimido-1-methylbutyl)amino>-5-<3-(trifluoromethyl)phenoxy>quinoline 
• 82333-37-7 6-methoxy-4-methyl-8-nitro-5-<3-(trifluoromethyl)phenoxy>quinoline 
• 80065-55-0 8-<(4-amino-1-methylbutyl)amino>-6-methoxy-4-methyl-5-<3-(trifluoromethyl)phenoxy>quinoline 
• 80065-56-1 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-(3-trifluoromethylphenoxy)quinoline succinate 
• 82333-41-3 8-amino-6-methoxy-4-methyl-5-(3-trifluoromethylphenoxy)quinoline 
• 1061346-40-4 C₁₄H₁₁F₃N₂O₄*ClH 

Relevant articles and documents

Inhibition of human monoamine oxidase A and B by 5-phenoxy 8-aminoquinoline analogs

8-Aminoquinolines (8-AQs) are important class of anti-infective therapeutics. 5-Phenoxy 8-aminoquinoline analogs have shown improved metabolic stability compared to primaquine. In view or predictive role of monoamine oxidases (MAO) in metabolism of 8-amin

COMPOUNDS AFFECTING GAP JUNCTION ACTIVITY

ThThis invention relates to novel quinoline compounds which affect gap junction activity. Also provided are methods of using such compounds and compositions containing the compounds to treat gap junction disorders.